(Total Views: 492)
Posted On: 04/09/2019 5:05:09 PM
Post# of 72436
I agree....my interpretation is IPIX is telling shareholders that the deal for B-OM will be substantial based upon their estimates for head and neck cancer in the US and Europe. As noted, that does not include the full market for other OM sufferers. I could be wrong and this only IMHO, but it sure seems like that is the underlying message.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)